@TEXTILE_FIBER@J55612435@RobertDurant7 I am building the connections now to hold those involved with slowing $sava down accountable. Most importantly to get investigations of the government actions taken to investigate cassava and associated parties.
$SAVA @elonmusk@RobertKennedyJr More information as to why I think simufilam will have a significant impact on Alzheimer’s APOE4 gene carriers.
Folks might remember my “All ROADS LEAD TO ROS” post here…. https://t.co/KPE2CKoTSV this has led to my model of mild and moderate disease here https://t.co/oEJ1K5uHZO and I have posted often about the potential of simufilam across diseases here and links therein…https://t.co/gdq5ZITqYB
Now I’d like to get into the differences between the proteins associated with APOE2, APOE3, APOE4 genes. See picture below obtained from a reference.
Notice for APOE4 that two important cysteine residues have been replaced by Arginine residues and this APOE4 is significantly linked to Alzheimer’s. It turns out that the APOE2 (with two cysteine’s intact) is linked to “protective” effects against Alzheimer’s. Why the difference?
Cysteine residues are critical for proteins and chemically react with ROS and lead to disulfide bonds (S-S). Thus under reductive conditions (low ROS) they exist as cysteine (SH) residues but under oxidative conditions (high ROS) they exist as di-sulfides (S-S). This is well known and established redox chemistry and a key tenant of cysteine residues in proteins.
APOE4 (proteins lacking these two cysteine residues) Alzheimer’s patients indeed have SIGNIFICANTLY higher ROS associated with disease. It’s also known that APOE4 leads to significant protein misfolding. Also the LDLR (low density lipoprotein receptor) binds significantly higher to the APOE4 protein. This APOE4 protein LDLR interaction is critical for cholesteral metabolism. Coincidentally, APOE4 has a higher risk for Atherosclerosis and cardiovascular disease.
For more on Atherosclerosis see my post here…https://t.co/NHAtSEcyNd
This interaction of APOE4 with LDLR has been shown to enhance amyloid-beta production https://t.co/cfnxyPKIyD through kinase activation pathways.
This kinase activation perfectly fits my model that leads to FLNA phosphorylation, which directly links to tau phosphorylation (my speculation post) through KRAS posted here and links therein….https://t.co/zgcLDqwYpa
FEW SHORT WEEKS AND WE FIND OUT WHAT SIMUFILAM CAN DO!
Reply to MattNachrab on his prediction for mild wrt to Donanemab results. Adding Dr Hendrix’s “ Time Saved” methodology for “Time Saved”.
Simufilam could be the best AD drug ever. Rethink results will confirm.
Given the late hour I wrote and submitted my last post, I failed to mention two supporters of $SAVA that have for years provided honest and compelling information about $SAVA. Both have worked tirelessly to alert retail investors of the emergence of what many, including me, believe to be the first truly safe and effective drug to treat patients suffering from Alzheimer's disease. They have produced videos that none of the shorts can honestly denounce. These two people are @JoeSpringer and @TruthfulHand. I urge anyone in the process of conducting their due diligence on $SAVA to view their videos related to $SAVA. After viewing their posts and videos, I believe you will agree $SAVA represents much more than a tug of war between bulls and bears. IMO, it is a struggle between good and evil.
Additionally, I extend my personal apology to each for not recognizing them in my original post as the have both contributed so much to enlighten the public of what's really going on behind the ticker symbol.
$SAVA @elonmusk@RobertKennedyJr Agree 100% with below that CORRUPT WALLSTREET are hoping to train Longs to sell at minimal returns in order to help them exit their disastrous short positions. Any one that has read my posts (and even from the company itself) knows that Cassava’s amazing FLNA-Simufilam discovery does NOT end with Alzheimer’s. It’s a GINORMOUS market in Alzheimer’s alone and easily becomes logarithmic as soon as the mechanism of action behind simufilam is applied to other diseases. This is the definition of a PLATFORM TECHNOLOGY!
Martin S is not a credible source and practices the same techniques as all the shorts. They are just throwing out a bunch of half baked theories and speaking like they are MUCH more knowledgeable than they actually are. They never cover positive information or angles. I am majorly diversified outside of sava. I think I’m right but okay risking it through the readout.
@MattNachtrab@RobertDurant7 He's a car salesman with a good vocabulary. I've spoken with some incredibly knowledgeable people. They even glazed over some of his "papers" out of curiosity. He has either chosen to argue in complete bad faith or completely lacks basic foundational knowledge...
I had a discussion with my assistant SAVA Dog , We are not selling a single share of Sava and waiting for P3 data , we are only weeks away from what could be the best Alzheimer’s drug available, very safe and effective, And the short sellers better get ready to lose everything.
$SAVA FDA changes prompted this post as I had been thinking ahead to implications of the Nov US election. Many focused on eliminating redtape and perceptions of a FDA revolving door, personally more focused on near term effects. Attached Reddit observation.